Resolvin E1 (RvE1) is an endogenous lipid mediator derived from the omega-3 fatty acid eicosapentaenoic acid (EPA). It exhibits anti-inflammatory properties, activates inflammation resolution, and promotes phagocytic clearance. It prevents 2,4,6-trinitrobenzenesulfonic acid-induced colitis and improves erythrocytosis and severe aplastic anaemia (SAA).

Resolvin E1 specifically interacts with the LTB4 receptor BLT1 on neutrophils and ChemR23 on monocytes to regulate leukocytes during inflammation. Resolvin E1 also stimulates the uptake and clearance of local cytokine. Resolvin E1 (0.1-100 nM) gives concentration-dependent inhibition of TNF-α–induced NF-κB activation (EC50: ～1.0 nM in ChemR23-transfected cells). Resolvin E1 (100 nM) enhances phosphorylation of ERK mitogen-activated protein (MAP) kinase both in peripheral blood monocytes and HEK-ChemR23 cells [2][3].

Resolvin E1 (1.0 μg per mouse; 50 μg/kg; i.p.; on days -8, -1, and 0) protects mice from TNBS colitis[1].